Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 1, 2001
Event: Acquisition of the business of Warner Instrument Corporation ("Warner").
Key Financial Metrics
Acquisition Details:
- Purchase Price: $2.6 million in cash.
- Liabilities: Assumption of certain operating liabilities.
- Accounting Method: Purchase method.
- Revenue (12 months ended Dec 31, 2000): $2.3 million (unaudited, net of sales to Harvard Bioscience).
- Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics regarding the combined entity or the target's profitability.
Material Changes
The primary material change is the expansion of the Company's operations through the acquisition of Warner's operating assets. This represents a strategic shift in the Company's asset base and potential revenue streams, though specific comparative financial impacts for the current period are not detailed in this report.
Guidance, Outlook, and Risks
Forward-Looking Statements: The report contains forward-looking statements subject to known and unknown risks and uncertainties. Actual results may differ materially from anticipated results.
Risk Disclosure: The Company disclaims any obligation to update forward-looking statements. Detailed risk factors are referenced in the "Important Factors That May Affect Future Operating Results" section of the Annual Report on Form 10-K for the year ended December 31, 2000.
Unusual Items: None reported beyond the acquisition transaction.
Investor Verification Checklist
- Verify the specific operating liabilities assumed from Warner Instrument Corporation.
- Review the Form 10-K for the year ended December 31, 2000, for detailed risk factors affecting future operating results.
- Confirm the integration timeline and expected synergies from the Warner acquisition, as these are not quantified in this 8-K.
- Assess the impact of the $2.6 million cash outlay on the Company's current liquidity position.